Rare neuropsychiatric focus Zynerba specializes in pharmaceutically-produced transdermal cannabinoids for rare and near-rare CNS disorders, presenting a niche opportunity to partner with patient advocacy groups, clinics, and specialty pharmacies serving Fragile X Syndrome, 22q11.2 Deletion Syndrome, and Autism.

Transdermal advantage The company touts a transdermal CBD delivery platform with potential safety and adherence benefits, creating sales angles for hospitals, specialty treatment centers, and home-health channels seeking non-oral cannabinoid therapies with improved tolerability.

Wholly-owned pipeline Zynerba emphasizes an in-house pipeline led by Zygel, enabling direct collaboration on regulatory strategy, clinical endpoints, and patient access programs, which can be leveraged to negotiate preferred supplier or milestone-based partnerships.

Clinical footprints Active development across Fragile X, 22q11.2 Deletion Syndrome, and Autism positions Zynerba as a potential early-access or investigational partner for specialty clinics, contract research organizations, and patient registries focusing on neurodevelopmental rare diseases.

Financial and partnerships Recent funding activity and equity arrangements indicate liquidity and collaboration interest from investors, suggesting openings for co-development, strategic licensing, and distribution deals that can accelerate market entry and expand reach.